Company Quick10K Filing
TYG Solutions
10-Q 2020-03-31 Filed 2020-05-14
10-K 2019-12-31 Filed 2020-03-30
10-Q 2019-09-30 Filed 2019-11-13
10-Q 2019-06-30 Filed 2019-08-13
10-Q 2019-03-31 Filed 2019-05-14
10-K 2018-12-31 Filed 2019-04-09
S-1 2018-10-05 Public Filing
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-07-24
10-K 2018-03-31 Filed 2018-07-24
10-K 2017-12-31 Filed 2018-07-24
10-Q 2017-09-30 Filed 2017-11-14
10-Q 2017-06-30 Filed 2017-08-18
10-Q 2017-03-31 Filed 2017-05-22
10-K 2016-12-31 Filed 2017-03-30
10-Q 2016-09-30 Filed 2016-11-21
10-Q 2016-06-30 Filed 2016-08-29
8-K 2020-03-12 Enter Agreement, Off-BS Arrangement, Sale of Shares, Exhibits
8-K 2020-01-28 Regulation FD, Exhibits
8-K 2018-10-04 Accountant, Exhibits
8-K 2018-07-25 Enter Agreement, M&A, Sale of Shares, Officers, Regulation FD, Exhibits
8-K 2018-07-24 Enter Agreement, Sale of Shares
8-K 2018-05-01 Shareholder Rights, Amend Bylaw, Shareholder Vote, Exhibits
8-K 2018-04-23 Accountant
8-K 2018-04-12 Accountant, Other Events, Exhibits
8-K 2018-03-05 Accountant, Exhibits

TYG Solutions Financials

TYGS Metrics, Comps, Filings

Quarterly | Annual

Business

We are a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from our proprietary cannabinoid product platform in a broad range of disease areas. In our 8 years of operations, we have been principally involved in the research and development of synthetic cannabidiol ("CBD") therapeutics through pre-clinical drug discovery and development processes. We have developed our own intellectual property portfolio and established relationships with globally recognized third parties who are considered leaders in active pharmaceutical ("API") contract manufacturers, formulators and contract bulk drug manufacturers. All of the operations of the Company to date have been in the pre-clinical stage of drug discovery.

CBD is a naturally occurring cannabinoid constituent of cannabis. It was discovered in 1940 and is known to exhibit neuroprotective properties in many experimental systems. However, development of CBD as a drug has been confounded by the following: 1) low potency; 2) a large number of molecular targets; 3) marginal pharmacokinetic properties; and 4) designation as a schedule 1 controlled substance. Our present work has compared the properties of CBD with our patented novel cannabidiol derived molecule, KLS-13019, that has structural similarities to CBD. The design strategy for KLS-13019 was to increase hydrophilicity while optimizing neuroprotective potency against oxidative stress toxicity relevant to hepatic encephalopathy. In early pre-clinical studies, the responses of CBD and KLS-13019 were compared in dissociated rat hippocampal cultures in a pre-clinical model for overt hepatic encephalopathy ("OHE") and also chemotherapy induced peripheral neuropathy ("CIPN").

Comparisons between CBD and KLS-13019 have been published in peer reviewed articles in ACS Medicinal Chemistry Letters (2016, 7, 424-428) and Journal of Molecular Neuroscience (14 August 2018). In the ACS abstract and paper, Notably, KLS-13019 was 50-fold more potent and >400-fold safer than cannabidiol and exhibited an in vitro profile consistent with improved oral bioavailability. In the JOMN abstract and paper, the protective responses of CBD and KLS-13019 were compared in dissociated rat hippocampal cultures co-treated with toxic levels of ethanol and ammonium acetate. This comparison revealed that KLS-13019 was 31-fold more potent than CBD in preventing neuronal toxicity from the combined toxin treatment, while both compounds exhibited complete protective efficacy back to control values.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Stemcell Holdings (STMM) 113% -1.0 26% 12,033 6,023 7,314 8,235 3,099 4,927 -5,116
FCCC (FCCC) 1.5 -61% 92 3 0 0 -56 -56 -82
Tapinator (TAPM) 0% 0.1 -99% 1,783 952 4,323 0 -1,762 -1,762 -260
Nogales Resources (NLRT) 0% 1 188 0 0 0 0 -1
Golden Growers Cooperative (GGRO) -0% 0% 26,919 2,171 42,425 -45 0 0 -3,508
Northern Power Systems (NPS) 22% 0.4 -27% 8,927 13,901 18,317 4,050 -2,379 -1,701 -670
Twin River Worldwide (TRWH) 0% 4.0 4% 1,070,918 808,153 393,158 0 41,775 112,100 449,560
Bio-En (BENH) 0.1 -643% 10 149 0 0 -67 -67 -5
Southwest Iowa Renewable Energy (SIRE) -1% -47.3 -1% 140,863 51,558 216,993 -1,931 -1,170 -537 25,396
Texas Republic Capital (TRCC) 0% 8.9 -5% 26,315 14,988 931 0 -1,274 -1,274 -11,328
Fannie Mae (FNM) 28.1 0% 3,494,436,000 3,484,094,000 0 0 13,025,000 119,732,000 3,361,548,000
CBA Florida (CBAI) 43.6 -1% 14,544 598 0 0 -211 -261 -11,368
Pacific Gold & Royalty (PCFG) -7.1 0 3,799 0 -3 -238 -45 320
BoxScore Brands (BOXS) 33% -8.3 -540% 313 7,564 338 110 -1,690 -702 5,793
Quest Management (QUEST) 27% -0.3 129% 13 6 45 12 16 16 -5
Zhen Ding Resources (RBTK) 0.1 48,309,900% 0 0 -483 -68 -6
Hines Global REIT (HGRI) 0% 1.7 19% 2,010,946 999,520 205,149 0 388,366 421,651 715,767
Wadena (WDN) 0% 0.0 -2,344% 12 696 87 0 -281 -278 -5
Galera Therapeutics (GRTX) 1.3 -17% 79,758 52,298 0 0 -13,351 -12,433 -15,719
Chase General (CSGN) 26% -0.5 -2% 1,563 1,016 2,493 658 -32 13 -7

Balance Sheet ($'000)2016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-09-302018-12-312019-03-312019-06-302019-09-30
Cash10000062472229307559537121
Accounts Receivable1010100000
Inventory
PP&E33379
Assets20101000624824,0743,0232,1641,443649
Accounts Payable51760011
Long-Term Debt2626000
Liabilities9536263040515521,5661,6921,6791,7401,612
Stockholders' Equity115-26-26-30-34-49-702,5081,331485-297-963
Income Statement ($'000)2016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue3500600038495324
Cost of Revenue210000000
Gross Profit1400600-50
R&D67101149189
SG&A36156441019350451459602
Tax000000000000
Net Income11-6-3113-4-15-21-799-846-784-1,086
Cash Flow ($'000)2016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating-2-19-0-10-4-9-30-473-830-697
Cash Investing725808280
Cash Financing-819010104500000